Cosmos Health stock fell 7.58 percent as Q2 growth held

Published on 10/07/2026 at 04:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cosmos Health stock carries a USD 0.3195 quote from October 6, 2026. Q2 revenue reached USD 18.99 million, up 28.8 percent year over year.

COSM, US2214133058, Illustration mit AI erstellt.

Cosmos Health stock (ISIN US2214133058) was last at USD 0.3195 on Nasdaq on October 6, 2026, down 7.58 percent from the prior close. The latest operating figures show a different signal: Q2 2026 revenue reached USD 18.99 million, up 28.8 percent year over year, according to ScanX.

Revenue growth stays visible

The company generated USD 36.91 million in first-half 2026 revenue, an increase of 29.7 percent from the prior-year period. The comparison matters because growth remained close to the Q2 rate rather than relying on a single quarter, although the stock still traded 75.8 percent below its 52-week high.

According to ScanX, total liabilities stood at USD 40.79 million on June 30, 2026, after declining 13.3 percent, while stockholders' equity rose 12.2 percent to USD 20.67 million. That combination gives the revenue increase a balance-sheet dimension.

New products widen the platform

Cosmos Health also received first orders for its C-ScrubVet veterinary antimicrobial line, with sales beginning in the United Kingdom on September 9, 2026, as ScanX reported. The product extends the existing C-Scrub platform into animal health and is manufactured at the company's Cana Laboratories facility.

The same report said the launch supports previously issued 2029 guidance for USD 200.6 million in revenue, USD 44.2 million in adjusted EBITDA and USD 31.0 million in net income. Those targets are forward-looking, so execution and conversion of initial orders into recurring distribution remain central to the investment case.

Profitability remains the test

Growth has not yet translated into positive earnings. Adjusted EBITDA was a loss of USD 1.13 million in Q2 2026, while the quarter's net income attributable to common shareholders was a loss of USD 6.09 million. The figures place the focus on operating leverage rather than revenue alone.

For investors, the clearest contrast is between a 28.8 percent quarterly revenue increase and continuing losses. The October 6 trading session added pressure, with the stock's USD 0.3195 price sitting inside a 52-week range of USD 0.1616 to USD 1.3200.

COSM stock stays below its yearly high

Cosmos Health stock was last at USD 0.3195 on Nasdaq on October 6, 2026, with volume of 4,469,282 shares. The market capitalization was USD 11.2 million on the same date, keeping the valuation sensitive to each new revenue and funding update.